$239.68
0.000.00%
Pre-Market: 4:25 PM EDT
Comments
Loading...
Labcorp Hldgs Insider Trading Activity | NYSE:LH | Benzinga
Track the latest Labcorp Hldgs insider trading activity. Stay informed on recent buys, sells, and market impact for Labcorp Hldgs stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Labcorp Holdings Inc Insiders Doing?
At Labcorp Holdings Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 3.83K shares worth $1.45M, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On February 26, 2025, Amy B Summy, the company's EVP, CHIEF MARKETING OFFICER sold 226 shares for $250.4 each.
- On February 20, 2025, Peter J Wilkinson, the company's SVP, CHIEF ACCOUNTING OFFICER sold 351 shares for $204.86 each.
- On March 7, 2025, Kerrii B Anderson, the company's DIRECTOR sold 500 shares for $255.63 each.
Ownership Statistics for Labcorp Holdings Inc
Shares Outstanding
83.700M
Insider Shares Owned
1.255M
Insider Percentage Owned
1.50%
Institutional Shares Held
56.803M
Institutional Percentage Held
67.9%
| Mar 07, 2025 | Kerrii B Anderson | DIRECTOR | -500.00 | $255.63 | -$127.82K | SELL | -3.62% | 13.31K | Mar 05 | View |
| Mar 04, 2025 | Mark S Schroeder | EVP, PRES DIAGNOSTICS & COO | -1.44K | $190.33 | -$817.67K | SELL | -22.45% | 4.96K | Feb 28 | View |
| Feb 27, 2025 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -1.31K | $251.30 | -$330.21K | SELL | -37.71% | 2.17K | Feb 25 | View |
| Feb 26, 2025 | Amy B Summy | EVP, CHIEF MARKETING OFFICER | -226.00 | $250.40 | -$56.59K | SELL | -4.74% | 4.54K | Feb 24 | View |
| Feb 20, 2025 | Peter J Wilkinson | SVP, CHIEF ACCOUNTING OFFICER | -351.00 | $204.86 | -$116.53K | SELL | -14.97% | 1.99K | Aug 01 - Feb 18 | View |
| Feb 13, 2025 | Adam H Schechter | PRESIDENT & CEO | -4.38K | $244.71 | -$1.80M | SELL | -4.74% | 88.18K | Feb 11 | View |
| Jan 08, 2025 | Kerrii B Anderson | DIRECTOR | -1.00K | $235.00 | -$235.00K | SELL | -7.21% | 12.87K | Jan 07 | View |
| Dec 04, 2024 | Glenn A Eisenberg | EXECUTIVE VICE PRESIDENT | 0.00 | $226.32 | -$330.50K | SELL-OPTIONS | 0.00% | 31.29K | Dec 02 | View |
| Dec 04, 2024 | Dwight Gary Gilliland | DIRECTOR | -1.00K | $241.00 | -$241.00K | SELL | -11.48% | 7.71K | Dec 02 | View |
| Nov 26, 2024 | Amy B Summy | EVP, CHIEF MARKETING OFFICER | 343.50 | $203.71 | -$200.53K | SELL-OPTIONS | 8.64% | 4.32K | Nov 22 | View |
| Nov 25, 2024 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -1.00K | $239.42 | -$239.42K | SELL | -27.25% | 2.67K | Nov 21 | View |
| Nov 13, 2024 | Adam H Schechter | PRESIDENT & CEO | -6.19K | $243.47 | -$1.51M | SELL | -6.61% | 87.44K | Nov 11 | View |
| Oct 25, 2024 | Kerrii B Anderson | DIRECTOR | -1.00K | $230.00 | -$230.00K | SELL | -6.73% | 13.87K | Oct 24 | View |
| Aug 21, 2024 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -2.00K | $227.05 | -$454.10K | SELL | -35.27% | 3.67K | Aug 19 | View |
| Aug 19, 2024 | Glenn A Eisenberg | CHIEF FINANCIAL OFFICER, EVP | -15.00K | $223.99 | -$3.36M | SELL | -32.41% | 31.29K | Aug 15 | View |
| Aug 09, 2024 | Kerrii B Anderson | DIRECTOR | -1.00K | $225.00 | -$225.00K | SELL | -6.30% | 14.87K | Aug 07 - Aug 08 | View |
| Aug 07, 2024 | Lance Berberian | EVP, CIO & CTO | -12.09K | $229.10 | -$2.77M | SELL | -43.17% | 15.92K | Aug 05 | View |
| May 16, 2024 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -2.00K | $210.83 | -$421.66K | SELL | -26.19% | 5.64K | May 14 | View |
| May 02, 2024 | Kerrii B Anderson | DIRECTOR | -500.00 | $202.12 | -$101.06K | SELL | -3.06% | 15.87K | Apr 30 - May 02 | View |
| May 01, 2024 | Peter J Wilkinson | SVP, CHIEF ACCOUNTING OFFICER | -2.44K | $204.33 | -$498.36K | SELL | -53.89% | 2.09K | Apr 29 | View |
| Apr 03, 2024 | Mark S Schroeder | EVP, PRES DIAGNOSTICS & COO | -6.48K | $217.29 | -$1.41M | SELL | -56.26% | 5.04K | Apr 01 | View |
| Apr 03, 2024 | Amy B Summy | EVP, CHIEF MARKETING OFFICER | -3.50K | $217.29 | -$760.51K | SELL | -46.82% | 3.98K | Apr 01 | View |
| Mar 29, 2024 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 0.00 | $216.67 | -$1.33M | SELL-OPTIONS | 0.00% | 7.64K | Mar 27 - Mar 28 | View |
| Mar 11, 2024 | Mark S Schroeder | EVP, PRES DIAGNOSTICS & COO | -2.93K | $167.77 | -$854.62K | SELL | -36.77% | 5.04K | Mar 07 | View |
| Mar 11, 2024 | Amy B Summy | EVP, CHIEF MARKETING OFFICER | -227.00 | $218.45 | -$49.59K | SELL | -5.56% | 3.86K | Mar 07 | View |
| Feb 22, 2024 | Glenn A Eisenberg | CHIEF FINANCIAL OFFICER, EVP | -20.45K | $189.80 | -$5.15M | SELL | -46.43% | 23.59K | Feb 21 | View |
| Feb 22, 2024 | Jonathan P DiVincenzo | EVP, PRES, CENTRAL LABS & INTL | -500.00 | $215.49 | -$107.75K | SELL | -12.82% | 3.40K | Feb 21 | View |
| Feb 15, 2024 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -237.00 | $226.45 | -$53.67K | SELL | -3.01% | 7.64K | Feb 13 | View |
| Feb 09, 2024 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -259.00 | $222.06 | -$57.51K | SELL | -3.28% | 7.64K | Feb 08 | View |
| Feb 06, 2024 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 0.00 | $220.83 | -$58.30K | SELL-OPTIONS | 0.00% | 7.64K | Feb 02 - Feb 05 | View |
| Nov 20, 2023 | Peter J Wilkinson | SVP, CHIEF ACCOUNTING OFFICER | -1.38K | $210.71 | -$291.63K | SELL | -39.87% | 2.09K | Nov 16 | View |
| Aug 10, 2023 | Kerrii B Anderson | DIRECTOR | -5.00K | $211.57 | -$1.06M | SELL | -24.49% | 15.42K | Aug 08 | View |
| Jul 03, 2023 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -212.00 | $240.00 | -$50.88K | SELL | -2.71% | 7.60K | Jun 29 | View |
| May 23, 2023 | Paul R Kirchgraber | CEO, COVANCE DRUG DEVELOPMENT | 0.00 | $199.71 | -$147.91K | SELL-OPTIONS | 0.00% | 12.95K | May 19 | View |
| May 22, 2023 | Mark S Schroeder | EVP, PRES DIAGNOSTICS & COO | 0.00 | $173.69 | -$129.25K | SELL-OPTIONS | 0.00% | 6.69K | May 18 | View |
| Apr 03, 2023 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | 0.00 | $225.34 | -$1.52M | GRANT | 0.00% | 6.69K | Mar 30 - Mar 31 | View |
| Feb 23, 2023 | Paul R Kirchgraber | CEO, COVANCE DRUG DEVELOPMENT | -5.00K | $216.55 | -$1.46M | SELL | -35.54% | 9.07K | Feb 21 | View |
| Feb 16, 2023 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | -309.00 | $247.63 | -$76.52K | SELL | -4.42% | 6.69K | Feb 14 | View |
| Feb 09, 2023 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -219.00 | $243.01 | -$53.22K | SELL | -3.94% | 5.34K | Feb 07 | View |
| Feb 09, 2023 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | -409.00 | $243.01 | -$99.39K | SELL | -5.76% | 6.69K | Feb 07 | View |
| Feb 06, 2023 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 0.00 | $254.19 | -$60.24K | SELL-OPTIONS | 0.00% | 5.34K | Feb 02 - Feb 03 | View |
| Feb 06, 2023 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | 0.00 | $254.19 | -$112.61K | SELL-OPTIONS | 0.00% | 6.69K | Feb 02 - Feb 03 | View |
| Nov 10, 2022 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | -1.12K | $232.67 | -$259.66K | SELL | -14.30% | 6.69K | Nov 08 | View |
| Sep 28, 2022 | Glenn A Eisenberg | CHIEF FINANCIAL OFFICER, EVP | -25.00K | $210.62 | -$5.27M | SELL | -47.93% | 27.16K | Sep 26 | View |
| Sep 13, 2022 | Brian J Caveney | EVP, PRESIDENT DIAGNOSTICS | 44.34 | $231.20 | $10.25K | BUY | 0.31% | 14.28K | Sep 07 | View |
| Aug 05, 2022 | Glenn A Eisenberg | CHIEF FINANCIAL OFFICER, EVP | 0.00 | $200.53 | -$3.43M | SELL-OPTIONS | 0.00% | 52.16K | Aug 03 | View |
| Aug 03, 2022 | Peter J Wilkinson | SVP, CHIEF ACCOUNTING OFFICER | -1.78K | $202.49 | -$559.13K | SELL | -48.21% | 1.91K | Aug 01 | View |
| Jun 14, 2022 | Brian J Caveney | EVP, PRESIDENT DIAGNOSTICS | 42.01 | $242.19 | $10.17K | BUY | 0.30% | 14.17K | Jun 07 | View |
| Mar 31, 2022 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | -2.36K | $277.11 | -$652.87K | SELL | -26.29% | 6.61K | Mar 29 | View |
| Mar 31, 2022 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -2.45K | $277.11 | -$678.64K | SELL | -31.66% | 5.29K | Mar 29 | View |
| Mar 29, 2022 | R. Sanders Williams | DIRECTOR | -572.00 | $272.98 | -$156.14K | SELL | -8.17% | 6.43K | Mar 25 | View |
| Mar 14, 2022 | Amy B Summy | EVP, CHIEF MARKETING OFFICER | -249.00 | $262.21 | -$65.29K | SELL | -49.90% | 250.00 | Mar 10 | View |
| Feb 18, 2022 | Peter M Neupert | DIRECTOR | 3.50K | $263.66 | $922.82K | BUY | 51.82% | 10.25K | Feb 16 | View |
| Feb 17, 2022 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | -207.00 | $273.98 | -$56.71K | SELL | -3.04% | 6.61K | Feb 15 | View |
| Feb 17, 2022 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -207.00 | $273.98 | -$56.71K | SELL | -3.77% | 5.29K | Feb 15 | View |
| Feb 08, 2022 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | 204.00 | $277.42 | -$98.76K | SELL-OPTIONS | 3.19% | 6.61K | Feb 04 - Feb 07 | View |
| Feb 08, 2022 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 0.00 | $277.41 | -$83.22K | SELL-OPTIONS | 0.00% | 5.29K | Feb 04 - Feb 07 | View |
| Feb 04, 2022 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | 161.00 | $272.40 | -$76.82K | SELL-OPTIONS | 2.58% | 6.40K | Feb 02 - Feb 03 | View |
| Feb 04, 2022 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 0.00 | $272.18 | -$64.23K | SELL-OPTIONS | 0.00% | 5.29K | Feb 02 - Feb 03 | View |
| Dec 17, 2021 | Dwight Gary Gilliland | DIRECTOR | -500.00 | $302.26 | -$151.13K | SELL | -7.41% | 6.25K | Dec 15 | View |
| Sep 17, 2021 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 0.00 | $190.82 | -$953.64K | SELL-OPTIONS | 0.00% | 5.26K | Sep 15 | View |
| Jun 09, 2021 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 0.00 | $175.71 | -$817.65K | SELL-OPTIONS | 0.00% | 5.24K | Jun 07 | View |
| May 10, 2021 | Paul R Kirchgraber | CEO, COVANCE DRUG DEVELOPMENT | -2.50K | $276.55 | -$691.38K | SELL | -24.17% | 7.84K | May 06 | View |
| May 05, 2021 | Jean-Luc Belingard | DIRECTOR | 0.00 | $183.82 | -$443.73K | SELL-OPTIONS | 0.00% | 15.57K | May 03 | View |
| Apr 01, 2021 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | -667.00 | $251.88 | -$168.00K | SELL | -11.76% | 5.01K | Mar 30 | View |
| Apr 01, 2021 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | -812.00 | $251.88 | -$204.53K | SELL | -13.42% | 5.24K | Mar 30 | View |
| Feb 19, 2021 | Peter J Wilkinson | SVP, CHIEF ACCOUNTING OFFICER | 453.00 | $199.14 | -$282.00K | SELL-OPTIONS | 86.58% | 976.22 | Feb 12 - Feb 18 | View |
| Feb 17, 2021 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 207.00 | $237.29 | -$86.85K | SELL-OPTIONS | 4.91% | 4.43K | Feb 12 - Feb 16 | View |
| Feb 17, 2021 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | 187.00 | $237.58 | -$78.40K | SELL-OPTIONS | 4.50% | 4.34K | Feb 12 - Feb 16 | View |
| Feb 08, 2021 | Sandra D. van der Vaart | EVP, CHIEF LEGAL OFFICER | 108.00 | $224.96 | -$43.19K | SELL-OPTIONS | 2.63% | 4.22K | Feb 04 - Feb 05 | View |
| Feb 08, 2021 | Mark S Schroeder | EVP, PRESIDENT-DIAGNOSTICS LAB | 203.00 | $224.96 | -$80.31K | SELL-OPTIONS | 5.14% | 4.15K | Feb 04 - Feb 05 | View |
| Nov 10, 2020 | Mark S Schroeder | — | -588.00 | $214.59 | -$126.18K | SELL | -12.96% | 3.95K | Nov 06 | View |
| Nov 06, 2020 | Paul R Kirchgraber | — | -1.50K | $214.14 | -$321.20K | SELL | -16.31% | 7.70K | Nov 04 | View |
| Jul 10, 2020 | R. Sanders Williams | — | 0.00 | $135.81 | -$97.02K | OPTION EXERCISE | 0.00% | 5.09K | Jul 08 | View |
| Jul 07, 2020 | Sandra D. van der Vaart | — | -435.00 | $170.00 | -$73.95K | SELL | -9.71% | 4.04K | Jul 02 | View |
| Jun 26, 2020 | Sandra D. van der Vaart | — | -872.00 | $160.33 | -$139.81K | SELL | -16.30% | 4.48K | Jun 24 | View |
| May 07, 2020 | David P King | — | -31.25K | $160.00 | -$5.00M | SELL | -8.60% | 332.10K | May 05 | View |
| May 04, 2020 | Judith C Seltz | — | 580.00 | $171.31 | $99.36K | PURCHASE | ∞ | 580.00 | Feb 28 - Mar 10 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.